Última actualización 19 de junio de 2026
Key finding
Supplementation increased 24-h urine magnesium excretion (P < 0.001)
This study evaluated the effects of six-month magnesium citrate supplementation on calciprotein crystallization and arterial stiffness in older individuals with type 2 diabetes and peripheral MAC, finding no significant reductions.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of six-month magnesium citrate supplementation on calciprotein crystallization and arterial stiffness in older individuals with type 2 diabetes and peripheral MAC, finding no significant reductions.
Understanding the effects of magnesium supplementation is crucial for managing cardiovascular health in older adults with type 2 diabetes. The lack of significant reduction in calciprotein crystallization and arterial stiffness suggests that magnesium citrate may not be a beneficial intervention for improving vascular health in this population, highlighting the need for further research into effective treatments.
The study may have limited generalizability due to the specific population studied. Sample size and duration may not be sufficient to detect subtle effects. Potential confounding factors were not fully explored.
Published in
Publication details and source links for this paper.
Romain M, Joyce YX, Simon PN, et al. Six-month magnesium citrate supplementation did not reduce calciprotein crystallization and arterial stiffness in older individuals with T2DM with peripheral MAC. The American Journal of Clinical Nutrition. 2026;123(5):101299. doi:10.1016/j.ajcnut.2026.101299
Magnesium supplementation did not increase calciprotein crystallization (T 50) [β = 6 min, P = 0.491]
Magnesium supplementation did not increase carotid-femoral pulse wave velocity (cfPWV) [β = 0.5 m/s, P = 0.180]
Supplementation increased 24-h urine magnesium excretion (P < 0.001)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Magnesium citrate and 24-h urine magnesium excretion, Calciprotein crystallization (T 50), Carotid-femoral pulse wave velocity (cfPWV), and 1 more.
This study contributes evidence to
Primary intervention
Magnesium citrate
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
4
Evidence pairs
424
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Magnesium citrate → 24-h urine magnesium excretion
Magnesium citrate → 24-h urine magnesium excretion
Magnesium citrate → Calciprotein crystallization (T 50)
Magnesium citrate → Calciprotein crystallization (T 50)
Magnesium citrate → Carotid-femoral pulse wave velocity (cfPWV)
Magnesium citrate → Carotid-femoral pulse wave velocity (cfPWV)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Magnesium Supplements and 24-h urine magnesium excretion, Magnesium Supplements and Calciprotein crystallization (T 50).
This study contributes to the evidence on the following intervention-outcome relationships.
Diet and Nutrition
Diet and Nutrition
Curated evidence collections and hubs this study is part of.
All studies measuring 24-h urine magnesium excretion
Measures 24-h urine magnesium excretion as a key outcome.
All studies measuring Calciprotein crystallization (T 50)
Measures Calciprotein crystallization (T 50) as a key outcome.
All studies on Magnesium Supplements
Contributes to Magnesium Supplements evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Magnesium Supplements may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Serum magnesium
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
Magnesium citrate appears to improve 24-h urine magnesium excretion.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
24-h urine magnesium excretion
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Magnesium citrate for Calciprotein crystallization (T 50).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Calciprotein crystallization (T 50)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Magnesium citrate for Carotid-femoral pulse wave velocity (cfPWV).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Carotid-femoral pulse wave velocity (cfPWV)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
